Klaus G Parhofer1. 1. Medical Clinic II, Großhadern University Hospital, Ludwig-Maximilians-Universität München.
Abstract
BACKGROUND: Disorders of lipid metabolism are very common. They play an important role in the pathogenesis of atherosclerosis and can be effectively treated by lifestyle changes and drugs. METHODS: This review is based on pertinent literature retrieved by a selective search. RESULTS: The main disorders of lipid metabolism are LDL-hypercholesterolemia, hypertriglyceridemia, mixed hyperlipoproteinemia, and low HDL cholesterol. The lipoprotein(a) level can also be elevated either in isolation or in combination with other disorders of lipid metabolism. According to the current European recommendations, an LDL-cholesterol target value should be defined on the basis of the overall cardiovascular risk. If this risk is very high, as in patients with documented atherosclerosis, the target value should be set at <70 mg/dL (<1.8 mmol/L). If the risk is lower, higher target values can be set: <100 mg/dL (<2.6 mmol/L) or <115 mg/dL (<3.0 mmol/L). Lifestyle changes are an effective treatment mainly for patients with hypertriglyceridemia and mixed disorders of lipid metabolism. Lowering the LDL-cholesterol concentration with statins is by far the most important type of pharmacotherapy. Patients who cannot tolerate statins or whose cholesterol level is not adequately lowered can be given ezetimibe instead. PCSK9 antibodies have been available since the autumn of 2015; they can apparently lower the LDL-cholesterol level by more than 50% , but no endpoint trials have yet been reported. At present, they should only be given to carefully selected patients. Fibrates and omega-3 fatty acids have been found to prevent cardiovascular events in monotherapy trials but yield no added benefit when given together with statins. The design of these trials was faulty, however, and the utility of such combinations in patients with mixed disorders of lipid metabolism or hypertriglyceridemia cannot yet be definitively assessed. CONCLUSION: There is a causal relationship between hypercholesterolemia and the risk of vascular and cardiovascular events. A reduction of LDL cholesterol lessens the risk of cardiovascular events.
BACKGROUND:Disorders of lipid metabolism are very common. They play an important role in the pathogenesis of atherosclerosis and can be effectively treated by lifestyle changes and drugs. METHODS: This review is based on pertinent literature retrieved by a selective search. RESULTS: The main disorders of lipid metabolism are LDL-hypercholesterolemia, hypertriglyceridemia, mixed hyperlipoproteinemia, and low HDL cholesterol. The lipoprotein(a) level can also be elevated either in isolation or in combination with other disorders of lipid metabolism. According to the current European recommendations, an LDL-cholesterol target value should be defined on the basis of the overall cardiovascular risk. If this risk is very high, as in patients with documented atherosclerosis, the target value should be set at <70 mg/dL (<1.8 mmol/L). If the risk is lower, higher target values can be set: <100 mg/dL (<2.6 mmol/L) or <115 mg/dL (<3.0 mmol/L). Lifestyle changes are an effective treatment mainly for patients with hypertriglyceridemia and mixed disorders of lipid metabolism. Lowering the LDL-cholesterol concentration with statins is by far the most important type of pharmacotherapy. Patients who cannot tolerate statins or whose cholesterol level is not adequately lowered can be given ezetimibe instead. PCSK9 antibodies have been available since the autumn of 2015; they can apparently lower the LDL-cholesterol level by more than 50% , but no endpoint trials have yet been reported. At present, they should only be given to carefully selected patients. Fibrates and omega-3 fatty acids have been found to prevent cardiovascular events in monotherapy trials but yield no added benefit when given together with statins. The design of these trials was faulty, however, and the utility of such combinations in patients with mixed disorders of lipid metabolism or hypertriglyceridemia cannot yet be definitively assessed. CONCLUSION: There is a causal relationship between hypercholesterolemia and the risk of vascular and cardiovascular events. A reduction of LDL cholesterol lessens the risk of cardiovascular events.
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Frederick J Raal; Robert P Giugliano; Marc S Sabatine; Michael J Koren; Gisle Langslet; Harold Bays; Dirk Blom; Mats Eriksson; Ricardo Dent; Scott M Wasserman; Fannie Huang; Allen Xue; Moetaz Albizem; Rob Scott; Evan A Stein Journal: J Am Coll Cardiol Date: 2014-02-05 Impact factor: 24.094
Authors: Gerald F Watts; Samuel Gidding; Anthony S Wierzbicki; Peter P Toth; Rodrigo Alonso; W Virgil Brown; Eric Bruckert; Joep Defesche; Khoo Kah Lin; Michael Livingston; Pedro Mata; Klaus G Parhofer; Frederick J Raal; Raul D Santos; Eric J G Sijbrands; William G Simpson; David R Sullivan; Andrey V Susekov; Brian Tomlinson; Albert Wiegman; Shizuya Yamashita; John J P Kastelein Journal: Int J Cardiol Date: 2013-11-20 Impact factor: 4.164
Authors: Dirk J Blom; Tomas Hala; Michael Bolognese; Michael J Lillestol; Phillip D Toth; Lesley Burgess; Richard Ceska; Eli Roth; Michael J Koren; Christie M Ballantyne; Maria Laura Monsalvo; Kate Tsirtsonis; Jae B Kim; Rob Scott; Scott M Wasserman; Evan A Stein Journal: N Engl J Med Date: 2014-03-29 Impact factor: 91.245
Authors: C P Sparrow; C A Burton; M Hernandez; S Mundt; H Hassing; S Patel; R Rosa; A Hermanowski-Vosatka; P R Wang; D Zhang; L Peterson; P A Detmers; Y S Chao; S D Wright Journal: Arterioscler Thromb Vasc Biol Date: 2001-01 Impact factor: 8.311
Authors: Liya Wu; Katja Piotrowski; Tiina Rau; Elisa Waldmann; Uli C Broedl; Hans Demmelmair; Berthold Koletzko; Renee G Stark; Jutta M Nagel; Christos S Mantzoros; Klaus G Parhofer Journal: Metabolism Date: 2013-11-12 Impact factor: 8.694
Authors: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene Journal: N Engl J Med Date: 2004-03-08 Impact factor: 91.245
Authors: Anders Berg Jørgensen; Ruth Frikke-Schmidt; Børge G Nordestgaard; Anne Tybjærg-Hansen Journal: N Engl J Med Date: 2014-06-18 Impact factor: 91.245
Authors: Martin J Landray; Richard Haynes; Jemma C Hopewell; Sarah Parish; Theingi Aung; Joseph Tomson; Karl Wallendszus; Martin Craig; Lixin Jiang; Rory Collins; Jane Armitage Journal: N Engl J Med Date: 2014-07-17 Impact factor: 91.245
Authors: Magdalena Fernandez-Acosta; Juan I Romero; Guillermo Bernabó; Giovanna M Velázquez-Campos; Nerina Gonzalez; M Lucía Mares; Santiago Werbajh; L Amaranta Avendaño-Vázquez; Gerald N Rechberger; Ronald P Kühnlein; Cristina Marino-Buslje; Rafael Cantera; Carolina Rezaval; M Fernanda Ceriani Journal: BMC Biol Date: 2022-10-21 Impact factor: 7.364